脓毒性休克中血管升压药启动时间与死亡率增加无关
该研究为回顾性队列研究,基于OneFlorida Data Trust全州医疗数据,纳入2012至2018年间4,699例脓毒性休克患者,定义为住院期间至少1次低血压(收缩压≤100 mmHg)后接受血管升压药,且具有脓毒症ICD-9/10编码或感染编码并接受静脉抗生素。主要结局为90天死亡率,发生率为34%(n=1,610)。多因素logistic回归结合LASSO变量选择显示,血管升压药启动时间与90天死亡率无关(OR 1.01;95%CI 1.00至1.02),也与无血管升压药天数无关。独立预测因素包括年龄、机械通气、SOFA评分实验室组分、乳酸水平、慢性高血压和肝病。
要点
- 在4,699例脓毒性休克患者中,从首次低血压到启动血管升压药的时间与90天死亡率无关(OR 1.01;95%CI 1.00至1.02)。
- 90天死亡率为34%(n=1,610)。
- 机械通气(OR 2.98;95%CI 2.56至3.48)、乳酸水平(OR 1.10;95%CI 1.08至1.13)和肝病(OR 1.54;95%CI 1.30至1.82)为独立预测因素。
- 慢性高血压与90天死亡率呈负相关(OR 0.60;95%CI 0.52至0.70)。
- 血管升压药启动时间不是无血管升压药天数的独立预测因素。
适用人群与场景
- 脓毒性休克患者,纳入标准为住院期间至少1次低血压(收缩压≤100 mmHg)后接受血管升压药,且具有脓毒症ICD-9或ICD-10编码,或具有感染ICD编码并接受静脉抗生素。
诊断标准与关键阈值
- 脓毒性休克定义:住院期间至少1次低血压(收缩压≤100 mmHg)后接受血管升压药,且具有脓毒症ICD-9/10编码或感染ICD编码并接受静脉抗生素。
研究设计与关键结果
- 研究类型:回顾性队列研究,基于OneFlorida Data Trust全州医疗数据,纳入2012至2018年间4,699例脓毒性休克患者。
- 主要结局:90天死亡率34%(n=1,610)。
- 血管升压药启动时间与90天死亡率无关(OR 1.01;95%CI 1.00至1.02)。
- 独立预测因素:年龄(OR 1.04;95%CI 1.04至1.05)、机械通气(OR 2.98;95%CI 2.56至3.48)、SOFA评分实验室组分(OR 1.18;95%CI 1.14至1.23)、乳酸水平(OR 1.10;95%CI 1.08至1.13)、慢性高血压(OR 0.60;95%CI 0.52至0.70)、肝病(OR 1.54;95%CI 1.30至1.82)。
- 血管升压药启动时间不是无血管升压药天数的独立预测因素。
证据类型、等级与局限
- 证据类型:回顾性队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者结论:在这项大型脓毒性休克队列中,从首次低血压到启动血管升压药的时间与90天死亡率或无血管升压药天数无关。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
STUDY OBJECTIVE: The optimal timing of vasopressor initiation in septic shock remains unclear. Our objective was to evaluate the association between time to vasopressor initiation and mortality.
METHODS: This was a retrospective cohort study of patients with septic shock in the OneFlorida Data Trust, a statewide repository of health care data. We included patients if they received vasopressors during hospitalization after at least 1 episode of hypotension (systolic blood pressure ≤100 mmHg) and had either (1) an International Classification of Disease 9 or 10 code for sepsis, or (2) an International Classification of Disease code for infection and received IV antibiotics. The primary outcome was 90-day mortality. The secondary outcome was vasopressor-free days. We used multiple logistic regression with Least Absolute Shrinkage and Selection Operator for variable selection to assess associations with 90-day mortality.
RESULTS: There were 4,699 patients with septic shock between 2012 and 2018 included. The primary outcome, 90-day mortality, was present in 34% (n=1,610). Time to vasopressor initiation was not found to be associated with 90-day mortality (odds ratio [OR] 1.01; 95% confidence interval [CI] 1.00 to 1.02). Independent predictors included age (OR 1.04; 95% CI 1.04 to 1.05), mechanical ventilation (OR 2.98; 95% CI 2.56 to 3.48), laboratory components of the Sequential Organ Failure Assessment score (OR 1.18; 95% CI 1.14 to 1.23), lactate level (OR 1.10; 95% CI 1.08 to 1.13), chronic hypertension (OR 0.60; 95% CI 0.52 to 0.70), and liver disease (OR 1.54; 95% CI 1.30 to 1.82). Time to vasopressor initiation was not found to be an independent predictor of vasopressor-free days.
CONCLUSION: Time from first hypotensive episode to vasopressor initiation was not found to be associated with 90-day mortality or vasopressor-free days in this large cohort of septic shock patients.
参考来源
- Black LP, Hopson C, Puskarich MA, et al. Time to Vasopressor Initiation Is Not Associated With Increased Mortality in Patients With Septic Shock. Ann Emerg Med. 2025. PMID: 41186550. doi:10.1016/j.annemergmed.2025.09.024
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。